Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

337

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
Lung Adenocarcinoma Stage IIIB/IV

Interventions

DRUG: Tepotinib

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]